Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease

Journal of Infectious Diseases

Volumn 176, Issue 3, 1997, Pages 786-789

  Chou, Sunwen ^a   Marousek, Gail ^b   Guentzel, Susan ^b   Follansbee, Stephen E ^b   Poscher, Margaret E ^b   Lalezari, Jacob P ^b   Miner, Richard C ^b   Drew, W Lawrence ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; POL PROTEIN;

ADULT; ARTICLE; CASE REPORT; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; POINT MUTATION; PRIORITY JOURNAL; RETINITIS; VIRUS GENE; VIRUS ISOLATION; VIRUS RESISTANCE;

EID: 0030788134     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517302     Document Type: Article

References (13)

1. Crumpacker CS, ed. Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(suppl 1):S1-22.
2. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993;1:179-85.
3. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171:576-83.
4. Erice A, Gil-Roda C, Perez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997;175:1087-92.
5. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-5.
6. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-42.
7. Baldanti F, Sarasini A, Silini E, et al. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Scand J Infect Dis Suppl 1995;99:103-4.
8. Baldanti F, Silini E, Sarasini A, et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol 1995;69:796-800.
9. Hanson MM, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother 1995;39:1204-5.
10. Smith IL, Shinkai M, Freeman WR, Spector SA. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. J Infect Dis 1996, 173:1481-4.
11. Wolf DG, Lee DJ, Spector SA. Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob Agents Chemother 1995;39:2552-4.
12. Sullivan V, Biron KK, Talarico C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993;37:19-25.
13. Lurain NS, Thompson KD, Holmes EW, et al. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992;66:7146-52.